Search hospitals > Florida > Miami Beach

Mount Sinai Medical Center

Claim this profile
Miami Beach, Florida 33140
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
447 reported clinical trials
19 medical researchers
Photo of Mount Sinai Medical Center in Miami BeachPhoto of Mount Sinai Medical Center in Miami BeachPhoto of Mount Sinai Medical Center in Miami Beach

Summary

Mount Sinai Medical Center is a medical facility located in Miami Beach, Florida. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Mount Sinai Medical Center is involved with conducting 447 clinical trials across 470 conditions. There are 19 research doctors associated with this hospital, such as Michael A. Schwartz, Mike Cusnir, MD, Brian Slomovitz, and Oleg Gligich.

Area of expertise

1Breast Cancer
Global Leader
Mount Sinai Medical Center has run 80 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 positive
HER2 negative
2Lung Cancer
Global Leader
Mount Sinai Medical Center has run 74 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Mount Sinai Medical Center

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Pancreatic Cancer
Colorectal Cancer
Prostate Cancer
Urothelial Carcinoma
Image of trial facility.

Trastuzumab Deruxtecan

for Breast Cancer

This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor [HR]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Recruiting2 awards Phase 310 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mount Sinai Medical Center?
Mount Sinai Medical Center is a medical facility located in Miami Beach, Florida. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Mount Sinai Medical Center is involved with conducting 447 clinical trials across 470 conditions. There are 19 research doctors associated with this hospital, such as Michael A. Schwartz, Mike Cusnir, MD, Brian Slomovitz, and Oleg Gligich.
Where is Mount Sinai Medical Center located?
**Mount Sinai Medical Center - Miami Beach, FL** - **Address:** 4300 Alton Rd, Miami Beach, FL - **Directions:** Take I-195 E to the Alton Road exit. Head south on Alton Road for approximately one mile. - **Parking:** Visitor parking is available in the parking garage located at the hospital's address.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Mount Sinai Medical Center, patients can contact the Customer Service department at 305-674-2130, available Monday-Friday, 9:00am to 4:00pm. The Resource, Entitlement and Advocacy Program (REAP) assists with government health insurance programs and requires a referral by a Social Worker. The Charity Care Program offers financial aid to eligible patients; for application details, call the Financial Counseling Office at 212-979-4306.
What insurance does Mount Sinai Medical Center accept?
Mount Sinai Medical Center accepts a wide range of insurance plans for urgent care, including but not limited to: - Various Aetna plans (HMO, PPO/POS, Medicare) - Cigna plans (HMO, Indemnity, Open Access, POS, PPO/EPO) - Empire BCBS (PPO/POS/EPO, HMO, Healthy New York, Mediblue, Top Tier) - EmblemHealth (CBP PPO, CompreHealth NY Metro Network-HIP EPO/HMO) - HIP (EPO, Healthy NY Plan, HMO-Classic, Medicare Advantage) - United Healthcare (PPO/POS/EPO, HMO, Empire Plan, Medicare) - Other plans including 1199 National Benefit Fund, Fidelis, Healthfirst, Magnacare, Medicare, Oscar, Oxford plans, and PHCS/Multiplan. For the most current insurance information, please contact Mount Sinai Medical Center directly.
What awards or recognition has Mount Sinai Medical Center received?
Mount Sinai Medical Center in Miami Beach, Florida, is renowned for its high-quality care, underscored by numerous awards and recognitions. This institution has been acknowledged by the Agency for Healthcare Research and Quality (AHRQ) for its exceptional quality data. Its commitment to excellence is further bolstered by a robust focus on teaching and research.